Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hyloris Pharmaceuticals Sa | LSE:0AB6 | London | Ordinary Share | BE0974363955 | HYLORIS PHARMACEUTICALS ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 2,571 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.21M | -15.38M | -0.5493 | -10.38 | 0 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 14/3/2024 | 06:00 | UKREG | Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives |
| 14/3/2024 | 06:00 | UKREG | Hyloris Reports Full Year Results for 2023 & Provides Business Outlook |
| 14/3/2024 | 05:59 | UKREG | Communiqué à la requête de la FSMA sur les transactions avec QliniQ |
| 14/3/2024 | 05:59 | UKREG | Communication at the request of the FSMA on the transactions with Qliniq |
| 08/3/2024 | 06:00 | UKREG | Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024 |
| 08/3/2024 | 06:00 | UKREG | Hyloris to Report 2023 Full-Year Results on 14 March 2024 |
| 27/2/2024 | 17:00 | UKREG | Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In.. |
| 27/2/2024 | 17:00 | UKREG | Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son.. |
| 14/2/2024 | 17:00 | UKREG | Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary.. |
| 14/2/2024 | 17:00 | UKREG | Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de.. |
1 Year Hyloris Pharmaceuticals Chart |
Intraday Hyloris Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
